KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 7.2% – Time to Sell?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)’s share price dropped 7.2% during mid-day trading on Monday . The stock traded as low as $15.39 and last traded at $15.5860. Approximately 281,728 shares changed hands during trading, a decline of 83% from the average daily volume of 1,614,548 shares. The stock had previously closed at $16.80.

Analyst Ratings Changes

A number of equities research analysts have recently commented on KALV shares. HC Wainwright upped their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday. Needham & Company LLC boosted their target price on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $29.17.

KalVista Pharmaceuticals Price Performance

The business has a 50-day moving average of $14.57 and a 200 day moving average of $13.61. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The firm has a market capitalization of $828.45 million, a P/E ratio of -4.15 and a beta of -0.14.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. On average, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 5,296 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the transaction, the insider directly owned 131,831 shares of the company’s stock, valued at approximately $1,773,126.95. This trade represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian Piekos sold 4,471 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $60,134.95. Following the transaction, the chief financial officer owned 10,529 shares of the company’s stock, valued at $141,615.05. This represents a 29.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 31,329 shares of company stock worth $437,371. Insiders own 4.30% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Tudor Investment Corp ET AL bought a new position in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $24,360,000. Parkman Healthcare Partners LLC raised its position in KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after buying an additional 1,055,940 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in KalVista Pharmaceuticals by 2,258.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after acquiring an additional 905,053 shares in the last quarter. Freestone Grove Partners LP bought a new position in KalVista Pharmaceuticals during the 3rd quarter valued at $8,580,000. Finally, Schroder Investment Management Group boosted its holdings in KalVista Pharmaceuticals by 108.7% during the 3rd quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company’s stock worth $14,145,000 after acquiring an additional 603,499 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.